Synaptogenix (NASDAQ:TAOX) Posts Earnings Results

Synaptogenix (NASDAQ:TAOX) posted its earnings results on Thursday. The company reported ($1.83) earnings per share for the quarter, Zacks reports.

Synaptogenix Stock Performance

Shares of TAOX remained flat at $3.48 during mid-day trading on Thursday. 103,311 shares of the stock were exchanged, compared to its average volume of 146,936. The stock has a market cap of $26.00 million, a price-to-earnings ratio of -0.26 and a beta of 1.45. The firm has a 50-day moving average of $3.63 and a two-hundred day moving average of $4.42. Synaptogenix has a 12 month low of $3.18 and a 12 month high of $10.00.

Analysts Set New Price Targets

Several analysts recently issued reports on TAOX shares. Wall Street Zen upgraded Synaptogenix from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Synaptogenix has a consensus rating of “Sell”.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.